Experience of thrombotic microangiopathy unresponsive to therapeutic apheresis

Year 2019, Volume: 5 Issue: 1, 233 - 235, 04.01.2019

Hilmi Erdem Sümbül Onur Taktakoğlu

https://doi.org/10.18621/eurj.389830

Abstract

No abstract available.

Keywords

plasmapheresis, rituximab, thrombotic microanjiopathy

References

• [1] George JN. How I treat patients with thrombotic thrombocytopenic purpura:2010. Blood 2010;116:4060-9.
• [2] Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patient with thrombotic thrombocytopenic purpura. Blood 2010;115:1500-11.
• [3] George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 2006;21:49-56.
• [4] Ling HT, Field JJ, Blinder MA. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol 2009;84:418-21.
• [5] McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmakonetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010;8:1201-8.